Clinical trials: Empagliflozin
Non-Alcoholic Fatty Liver Disease, Liver Steatosis
Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)
The goal of this clinical study is to compare the therapeutic effect of Dulaglutide and Empagliflozin in patients with Diabetes Mellitus type 2 and Non-Alcoholic Fatty Liver Disease.
- Trial name
- NAMELS-18 (NCT05946148)
- Testing
- Empagliflozin, Dulaglutide, Control Rx
- Where
- Greece
- Volunteers
- 78 people
- Sponsor
- National and Kapodistrian University of Athens